By CARLA K. JOHNSON, AP Medical Writer
A combination shot for flu and COVID-19 using messenger RNA generated antibodies in a study, but U.S. government regulators want to see data on whether the new vaccine protects people from getting sick.
Related Articles
Critic of drug industry and COVID-19 measures to lead FDA vaccine program
Opinion: Why don’t we see older adults with autism? It’s history, not mystery
RFK Jr. exaggerates share of autistic population with severe limitations
FDA scrutiny of Novavax COVID-19 vaccine sparks uncertainty about other shots
Stanford study: When measles could return if vaccination rates continue to fall
Researchers from vaccine-maker Moderna reported in a study published Wednesday that the new combo shot generated a stronger immune response against COVID-19 and most strains of flu than existing standalone shots in people 50 and older. Side effects were injection site pain, fatigue and headaches. Moderna previously reported a summary of the results from the company-sponsored trial in 8,000 people.
The mRNA technology is used in approved COVID-19 and RSV shots, but has not yet been approved for a flu shot. Moderna believes mRNA could speed up production of flu shots compared with traditional processes that use chicken eggs or giant vats of cells. A combo shot also might improve vaccination rates, the researchers wrote in the study published in the Journal of the American Medical Association.
Dr. Greg Poland, who studies vaccine response at Mayo Clinic and was not involved in the new study, said he’s not convinced that a combo shot would be popular. And while flu comes in seasonal waves, COVID-19 has been spreading throughout the year, Poland said, posing challenges for how to time the shots to keep protection strong.
He’d also like to see data on how well the new shot protected people from infection and hospitalization.
The findings are based on measuring antibodies in participants’ blood after 29 days, an indication of short-term disease protection.
Last week, Moderna pushed its target date for the vaccine’s approval to 2026 after the Food and Drug Administration requested a more direct measure: how much the shot lowered the risk of disease.
“I agree in this case with FDA that efficacy data are important to see,” Poland said.
Health Secretary Robert F. Kennedy Jr. has cast doubt on the safety of mRNA vaccines, but Moderna President Stephen Hoge told investors in an earnings call last week that talks with the FDA were productive and “business as usual.”
Also last week, Novavax said the FDA was asking the company to run a new clinical trial of its protein-based COVID-19 vaccine after the agency grants full approval, sowing uncertainty about other vaccine updates.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
